IGM Biosciences (IGMS) Expected to Announce Quarterly Earnings on Thursday

IGM Biosciences (NASDAQ:IGMS) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect IGM Biosciences to post earnings of ($0.74) per share and revenue of $0.39 million for the quarter.

IGM Biosciences Stock Performance

NASDAQ IGMS opened at $1.31 on Thursday. IGM Biosciences has a one year low of $1.26 and a one year high of $22.50. The firm has a market cap of $77.90 million, a price-to-earnings ratio of -0.36 and a beta of 0.03. The firm has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $9.17.

Analysts Set New Price Targets

Several research analysts recently commented on IGMS shares. Truist Financial lowered their target price on IGM Biosciences from $12.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, January 10th. JPMorgan Chase & Co. upgraded IGM Biosciences from an “underweight” rating to a “neutral” rating in a report on Monday, January 13th. BMO Capital Markets restated a “market perform” rating and set a $2.00 target price (down previously from $21.00) on shares of IGM Biosciences in a research note on Friday, January 10th. Royal Bank of Canada downgraded IGM Biosciences from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $20.00 to $1.50 in a report on Friday, January 10th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $2.00 price objective (down previously from $48.00) on shares of IGM Biosciences in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.50.

About IGM Biosciences

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.